FDA Accepts Zipalertinib NDA, Sets Feb 2027 PDUFA Date; Cullinan Therapeutics Details Q1 & Pipeline
summarizeSummary
Cullinan Therapeutics announced that the U.S. FDA has accepted its New Drug Application (NDA) for zipalertinib for EGFR ex20ins NSCLC, setting a PDUFA target action date of February 27, 2027. This is a significant regulatory milestone, advancing the drug closer to potential commercialization. The company also reported Q1 2026 financial results, showing $393.3 million in cash and investments, providing a runway into 2029, consistent with previous disclosures. Additionally, Cullinan provided a comprehensive pipeline update, including plans to present initial clinical data for CLN-978 in SLE and RA at the EULAR 2026 Congress in June, with further multi-dose data expected in Q3 2026. Updates for other oncology and immunology programs are anticipated in H2 and Q4 2026, providing multiple upcoming catalysts for the stock. The FDA acceptance and clear PDUFA date de-risk a key asset and provide a concrete timeline for a potential approval decision.
At the time of this announcement, CGEM was trading at $15.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $921.2M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.